Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands.
Vos JR, Teixeira N, van der Kolk DM, Mourits MJ, Rookus MA, van Leeuwen FE, Collée M, van Asperen CJ, Mensenkamp AR, Ausems MG, van Os TA, Meijers-Heijboer HE, Gómez-Garcia EB, Vasen HF, Brohet RM; Hereditary Breast and Ovarian Cancer Research Group Netherlands; van der Hout AH, Jansen L, Oosterwijk JC, de Bock GH. Vos JR, et al. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2482-91. doi: 10.1158/1055-9965.EPI-13-1279. Epub 2014 Aug 7. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 25103822
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON). Saadatmand S, et al. Among authors: vos jr. Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20. Int J Cancer. 2014. PMID: 24789418 Free article.
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Vos JR, Oosterwijk JC, Aalfs CM, Rookus MA, Adank MA, van der Hout AH, van Asperen CJ, Gómez Garcia EB, Mensenkamp AR, Jager A, Ausems MG, Mourits MJ, de Bock GH; Hereditary Breast and Ovarian Cancer Research Group Netherlands. Vos JR, et al. Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1251-8. doi: 10.1158/1055-9965.EPI-16-0182. Epub 2016 Jun 8. Cancer Epidemiol Biomarkers Prev. 2016. PMID: 27277847
The BRCA1/2 Parent-of-Origin Effect on Breast Cancer Risk-Response.
Vos JR, Oosterwijk JC, Rookus MA, van der Hout AH, Mourits MJ, de Bock GH; all authors. Vos JR, et al. Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):285. doi: 10.1158/1055-9965.EPI-16-0947. Cancer Epidemiol Biomarkers Prev. 2017. PMID: 28167645 No abstract available.
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?
Teixeira N, van der Hout A, Oosterwijk JC, Vos JR; HEBON; Devilee P, van Engelen K, Meijers-Heijboer H, van der Luijt RB, Kriege M, Mensenkamp AR, Rookus MA, van Roozendaal KE, Mourits MJE, de Bock GH. Teixeira N, et al. Among authors: vos jr. Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26. Eur J Hum Genet. 2018. PMID: 29483665 Free PMC article.
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group. Vos JR, et al. J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080. J Natl Cancer Inst. 2020. PMID: 31076742 Free PMC article.
34 results